SCHEMBL4158434

SCHEMBL4158434

N#Cc1ccc(Cn2c(=O)[nH]cc(I)c2=O)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.43
FEN1 P39748 1/20 0.41
CYP19A1 P11511 4/20 0.40
GRIN1 Q05586 1/20 0.39
GRIN2B Q13224 1/20 0.39
HTR2C P28335 1/20 0.39
OPRM1 P35372 1/20 0.38
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 2/20 0.38
PIK3R1 P27986 1/20 0.37
PIK3CA P42336 1/20 0.37
SRC P12931 1/20 0.37
CA12 O43570 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
KMT2A Q03164 1/20 0.36
RIPK3 Q9Y572 1/20 0.36
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
USP2 O75604 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4165788 0.84 FEN1 (0.45) DAOFEN1CYP19A1GRIN1GRIN2B
SCHEMBL4156287 0.81 KMT2A (0.48) KMT2AUSP2
SCHEMBL4164688 0.80 ALDH1A1 (0.51) CYP19A1SRCKMT2A
SCHEMBL27335737 0.77 KDM4E (0.51) DAOKMT2A
SCHEMBL28245640 0.77 DAO (0.44) DAO
SCHEMBL4171496 0.76 P2RX4 (0.50) SRCKMT2A
SCHEMBL4160559 0.75 ALDH1A1 (0.46) DAOFEN1OPRM1CA12CA2
SCHEMBL4174008 0.72 DBH (0.36) DAOGRIN1GRIN2BKMT2A
SCHEMBL8231174 0.70 MIF (0.41) KMT2A
SCHEMBL7359654 0.69 PRMT5 (0.57) CYP19A1OPRM1CA12CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO disclosed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS TK1, LCK, FYN DAO 1019/4885FEN1 2454/4885CYP19A1 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.